NCT00694083 2024-05-21
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
15 trialsNCT01169532 2021-02-21
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Fox Chase Cancer Center
Phase 1 Completed
NCT00874731 2019-05-06
MK-8669-037
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01380184 2019-04-19
MK-8669-059
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01256268 2017-08-30
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01431547 2016-06-17
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00060632 2015-08-27
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00060645 2015-08-27
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01295632 2015-08-27
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00087451 2015-08-19
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00288431 2015-07-22
Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01071304 2015-04-10
Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00781846 2015-02-13
Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00112372 2015-02-12
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01220570 2015-01-21
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Merck Sharp & Dohme LLC
Phase 1 Completed